GlassScriptPhysician profile
Jamie S Kim
NPI 1053658005
$5,810.76
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $2,554 · 2023: $2,420 · 2024: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.67 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,088.67 | 2021-2024 | Tremfya |
| Genzyme Corporation | $738.42 | 2022-2023 | |
| Abbvie INC. | $730.46 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $596.71 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $550.02 | 2022-2024 | Ilumya, Winlevi |
| Lilly USA, LLC | $405.47 | 2022-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $285.55 | 2022-2024 | Dupixent |
| Galderma Laboratories, L.P. | $279.94 | 2021-2023 | |
| Leo Pharma INC. | $200.46 | 2021-2024 | Adbry |
| Amgen INC. | $199.14 | 2022-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $181.82 | 2022 | |
| Incyte Corporation | $173.49 | 2022-2024 | Opzelura |
| Genentech USA, INC. | $98.73 | 2022-2023 | Erivedge |
| Sumitomo Pharma America, INC. | $82.42 | 2024 | Myfembree |
| Sanofi-Aventis U.S. LLC | $66.99 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $25.84 | 2022-2023 | |
| Ucb, INC. | $24.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.18 | 2022 | |
| Strata Skin Sciences, INC. | $20.30 | 2023 | Xtrac |
| Verrica Pharmaceuticals INC. | $14.65 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.